Key Insights

Highlights

Treatment Research

5 treatments under study, led by 1 Escitalopram As Escitalopram Oxalate Tablet 2 Placebo Softgels

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
Not Applicable (2)

Trial Status

Not Yet Recruiting1
Recruiting1

Clinical Trials (2)

Showing 2 of 2 trials
NCT07893002Not ApplicableRecruitingPrimary

A Randomized, Open-Label, 52-Week Extension Study to Evaluate the Maintenance of Remission, Relapse Prevention, and Long-Term Safety of CreNeuroS™ in Patients With Major Depressive Disorder Who Achieved Remission Following an 8-Week Parent Study

NCT07645807Not ApplicableNot Yet RecruitingPrimary

Study to Evaluate the Adjunctive Effect of CreNeuroS™ CNS Fish Oil Plus Softgels in Patients With Major Depressive Disorder Receiving Escitalopram.

Showing all 2 trials

Research Network

Common Treatments

  • 1 Escitalopram As Escitalopram Oxalate Tablet 2 Placebo Softgels1
  • Creneuros Cns Fish Oil Plus Softgels 1 Capsule Orally Once Daily1
  • Creneuros Cns Fish Oil Plus Softgels 2 Capsule Orally Once Daily1
  • No Intervention1
  • 1 Escitalopram As Escitalopram Oxalate Tablet 2 Creneurostm Cns Fish Oil Plus Softgels1

Active Sponsors

  • Vivotech Research Lab Pvt Ltd2
  • Sichuan Credit Pharmaceutical Co Ltd2

Activity Timeline